Zioptan (PF)
| Zioptan (PF) | |
|---|---|
| DOSAGE | 1 gtt QPM |
| GENERIC | Tafluprost ophthalmic solution 0.0015% (PF) |
| SIZE | Single use containers | 30 or 90 pack |
| INDICATIONS | Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. |
| MECHANISM OF ACTION | Increase aqueous outflow |
| MICROBIOLOGY | prostaglandin | prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time. |
| CONTRAINDICATIONS & WARNINGS | Increase in pigmentation of the iris and periorbital tissues, increase in length of eyelashes, intraocular inflammation, macular edema. Contact lenses should be removed 15 minutes prior to instillation |
| PEDIATRIC USE | Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use |
| PREGNANCY | Pregnancy category C | There are no adequate and well-controlled studies in pregnant woman. Although animal reproduction studies are not always predictive of human response, ZIOPTAN® should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. |
| NOTE | Zioptan is preservative-free |